statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the...

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Equities research analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Get Free Report) in a research note issued on Saturday. The firm set a...

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis Galmed Announces Grant of New Patent for the...

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the...

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD  Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average...

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Passes Below 200-Day Moving Average of $0.47

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Free Report) in a research note published on Saturday morning. The firm issued a sell rating on the...

Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Get Free Report) in a report released on Friday. The brokerage set a sell rating on the...

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Volume	66,362.00
52-Wk High	$7.80
52-Wk Low	$0.26

GLMD Galmed Pharmaceuticals Ltd

About

Feed

News

Sentiment

Fundamentals